Stryker's Mobius Imaging Buyout To Boost Its Spine Division

 | Sep 05, 2019 07:54AM ET

Stryker Corporation (NYSE:SYK) recently announced an agreement to acquire Mobius Imaging for a deal value of $370 million upfront and up to $130 million of contingent payments. Expected to close in the fourth quarter of 2019, this transaction is likely to remain neutral to Stryker’s net earnings in the year.

For investors’ notice, Massachusetts-based Mobius Imaging provides intelligent and clear images in clinical settings to healthcare practitioners, thereby improving patient outcome.

How Does Stryker Stand to Gain?

Per management, with the latest buyout, Stryker’s Spine division is likely to foray into the intra-operative imaging space, which aligns with its implant offerings. Notably, Mobius Imaging’s Airo TruCT scanner — a real-time, diagnostic-quality CT imaging system — is expected to complement Stryker’s Spine division.

Speaking of the Spine division, it comes with a comprehensive portfolio for orthopedic surgeons and neurosurgeons specializing in spine surgery. The segment offers a broad spectrum of products like interbody devices, radiofrequency ablation products, devices used for spine navigation and cervical fixation, and many more.

In the second quarter, the segment witnessed double-digit improvement and organic growth of 12.4%.

Stryker Rides on Acquisitions

It is encouraging to note that, Stryker’s recent acquisition of K2M is also expected to be accretive for the Spine division.

Earlier this year, Stryker acquired Arrinex a California-based medical device company, with a view to expand its Ear, Nose and Throat portfolio, which is part of the Spine division.

Some other notable acquisitions include that of HyperBranch Medical Technology and Invuity.

Market Prospects

.

Baxter’s long-term earnings growth rate is expected to be 12.8%.

Medtronic’s long-term earnings growth rate is projected at 7.3%.

Surmodics’ long-term earnings growth rate is expected to be 10%.

It’s Illegal in 42 States, But Investors Will Make Billions Legally

In addition to the companies you read about above, today you get details on the newly-legalized industry that’s tapping into a “habit” that Americans spend an estimated $150 billion on every year.

That’s twice as much as they spend on marijuana, legally or otherwise.

Zacks special report revealing how investors can profit from this new opportunity. As more states legalize this activity, the industry could expand by as much as 15X. Zacks’ has just released a Special Report revealing 5 top stocks to watch in this space.

Get The News You Want
Read market moving news with a personalized feed of stocks you care about.
Get The App

Zacks Investment Research

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Sign out
Are you sure you want to sign out?
NoYes
CancelYes
Saving Changes